SCHEMBL9732202

SCHEMBL9732202

COc1ccc(C(O)CCCC(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.57
AOC3 Q16853 2/20 0.50
GAA P10253 1/20 0.48
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
FFAR1 O14842 2/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LDHA P00338 1/20 0.45
GRM8 O00222 1/20 0.45
GRM6 O15303 1/20 0.45
GRM4 Q14833 1/20 0.45
PTGFR P43088 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9732195 1.00 PDE4B (0.57) PDE4BAOC3GAAHTTNPSR1
SCHEMBL5490631 0.95 PDE4B (0.53) PDE4BAOC3GAAFFAR1ALDH1A1
SCHEMBL7832869 0.95 PDE4B (0.55) PDE4BAOC3GAAHTTNPSR1
SCHEMBL8015785 0.94 PDE4B (0.54) PDE4BAOC3GAAHTTNPSR1
SCHEMBL6807907 0.92 AOC3 (0.51) PDE4BAOC3GAAHTTNPSR1
SCHEMBL9391332 0.83 PDE4B (0.57) PDE4BHTTNPSR1FFAR1NPC1
SCHEMBL6831514 0.82 AOC3 (0.49) PDE4BAOC3GAAALDH1A1MAPT
SCHEMBL2743314 0.81 KMT2A (0.47) FFAR1L3MBTL1PTGFRKMT2A
SCHEMBL4478662 0.81 FFAR1 (0.56) AOC3FFAR1L3MBTL1LDHAKMT2A
SCHEMBL4478666 0.81 FFAR1 (0.56) AOC3FFAR1L3MBTL1LDHAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210220442-A1 PEGylated Recombinant Human Growth Hormone Compounds ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2021-07-22 US disclosed
CN-107827952-A One plan peptides with the protease inhibiting activities of HIV 1 newly and its production and use 中国医学科学院医药生物技术研究所 2018-03-23 CN disclosed
US-5149462-A Used as ferroelectric liquid crystal MITSUBISHI RAYON COMPANY LTD. (JP) 1992-09-22 US disclosed
EP-0409066-A2 Optically active compound for liquid crystal and its use MITSUBISHI RAYON COMPANY, LTD. (JP) 1991-01-23 EP disclosed
US-4839360-A ANTIDEPRESSANTS; NERVOUS AND PSYCHOLOGICAL DISORDERS; COGNITION ACTIVATORS TANABE SEIYAKU CO., LTD. (JP) 1989-06-13 US disclosed
EP-0270093-A2 Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties TANABE SEIYAKU CO., LTD. (JP) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210220442-A1 PEGylated Recombinant Human Growth Hormone Compounds GHRHR, GHITM, GHSR PDE4B 4386/4885AOC3 4003/4885GAA 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.